Directed evolution,' which induces mutations in genetic material to create useful functions, is considered a core technology ...

A new phase 2 clinical trial suggests that a chemotherapy-free, minimal residual disease (MRD)–driven treatment strategy may offer durable remissions and the possibility of time-limited therapy for ...

Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...

You might think it's harmless to drink a glass of wine the night before surgery - because, nerves, right? However, there is a reason doctors advise against it.

Researchers identified trimethylamine (TMA) as a gut microbe–derived metabolite that directly inhibits IRAK4 to reduce ...

A tiny fleet of gold nanorobots is teaching stem cells how to become bone. At the same time, another lab is using gentle ...

Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...

Piper Sandler 37th Annual Healthcare Conference December 3, 2025 8:30 AM ESTCompany ParticipantsDavid Amsellem - MD & Senior ...

Ouroboros doesn’t like wet tracks so there is a growing induction Hoysted could deploy Ouroboros in the Listed Starlight ...